Īrija - angļu - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - hyaluronidase - powder for solution for injection/infusion - 1500 international unit(s) - enzymes; hyaluronidase

Īrija - angļu - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - hyaluronidase - powder for solution for injection/infusion - 1500 international unit(s) - enzymes; hyaluronidase

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - 1.1 subcutaneous fluid administration hylenex recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2 dispersion and absorption of injected drugs hylenex recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. 1.3 subcutaneous urography hylenex recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. hylenex recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in hylenex recombinant. a preliminary skin test for hypersensitivity to hylenex recombinant can be performed. the skin test is made by an intradermal injection of approximately 0.02 ml (3 units) of a 150 unit/ml solution. a positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. transient vasodilation at the site of the test, i.e., erythema, is

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

antares pharma, inc. - hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - hyaluronidase (human recombinant) 150 [usp'u] in 1 ml - hylenex recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. hylenex recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. hylenex recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. hylenex recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in hylenex recombinant. discontinue hylenex recombinant if sensitization occurs. risk summary there are no adequate and well-controlled studies of hylenex recombinant administration in pregnant women to inform a drug-associated risk. subcutaneous administration of hylenex recombinant to pregnant mice throughout organogenesis did not produce teratogenic effects at clinically relevant doses. administration of hylenex recombinant to mice in a pre-/postnatal study did not produce adverse effects on offspring at clinically relevant doses. human data limited available data with hylenex recombinant in pregnant women have not identified any potential risks. animal data in an embryofetal development study, subcutaneous administration of hyaluronidase to pregnant mice throughout organogenesis produced reduced fetal weight and increased numbers of fetal resorptions at daily doses greater or equal to 3 mg/kg (approximately 360,000 usp units/kg). no malformations were produced at any dose up to approximately 18 mg/kg (approximately 2,200,000 usp units/kg). these doses are several orders of magnitude greater than the maximum recommended human dose (5 usp units/kg). in a pre- and postnatal development study, mice were dosed daily by subcutaneous injection with hyaluronidase at dose levels up to 9 mg/kg (approximately 1,100,000 usp units/kg). the study found no adverse effects on sexual maturation, learning and memory of offspring, or their ability to produce another generation of offspring. risk summary there is no information regarding the presence of hylenex recombinant in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of hylenex recombinant to an infant during lactation. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for hylenex recombinant. clinical hydration requirements for children can be achieved through administration of subcutaneous fluids facilitated with hylenex recombinant. the dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. the potential for chemical or physical incompatibilities should be kept in mind [see drug interactions (7)]. the rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. for premature infants or during the neonatal period, the daily dosage should not exceed 25 ml/kg of body weight, and the rate of administration should not be greater than 2 ml per minute. during subcutaneous fluid administration, special care must be taken in pediatric patients to avoid over hydration by controlling the rate and total volume of the infusion [see dosage and administration (2.1)]. no overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

ulab - hyaluronic acid (unii: s270n0trqy) (hyaluronic acid - unii:s270n0trqy) - hyaluronic acid 0.15 g in 50 ml - purpose: skin hydrating and moisturizing indications & usage: apply morning and night

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

junmok international,inc - hyaluronate sodium (unii: yse9ppt4th) (hyaluronic acid - unii:s270n0trqy) - purpose: skin protectant indications & usage:1. take a patch out of the pouch with dry hand after face washing. 2. try not to touch the middle side (needle) and take off the protective film carefully. 3. place and attach the middle side of the patch on a desired area vertically. 4. press the middle part of the patch attached with fingers several times. 5. go to bed with patch attached and take it off the next morning.

Malta - angļu - Malta Medicines Authority

pinewood laboratories ltd ballymacarbry, clonmel, co. tipperary, ireland - hyaluronidase - powder for solution for infusion or injection - hyaluronidase 1500 iu/ml - other hematological agents

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

akorn, inc. - hyaluronidase (unii: 8kog53z5em) (hyaluronidase - unii:8kog53z5em) - hydase™ (hyaluronidase injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs. hydase™ is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. hydase™ is indicated as an adjuvant in subcutaneous urography for improving resorption of radiopaque. hydase™ contraindicated in patients with known hypersensitivity to hyaluronidase or any other ingredient in the formulation. a preliminary skin test for hypersensitivity to hydase™ can be performed. the skin test is made by an intradermal injection of approximately 0.02 ml (3 units) of a 150 unit/ml solution [see dosage and administration (2) ]. a positive reaction consists of a wheal with pseudopods appearing within five minutes and persisting for 20 to 30 minutes and accompanied by localized itching. transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. discontinue hydase™ if sensitization occurs. no adequate and well controlled animal studi

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

amphastar pharmaceuticals, inc. - hyaluronidase (unii: 8kog53z5em) (hyaluronidase - unii:8kog53z5em) - amphadase® is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. amphadase® is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. amphadase® is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. hypersensitivity to hyaluronidase or any other ingredient in the formulation is a contraindication to the use of this product. a preliminary skin test for hypersensitivity to amphadase® can be performed. the skin test is made by an intradermal injection of approximately 0.02 ml (3 units) of a 150 unit/ml solution. a positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. discontinue amphadase® if sensitization occurs. pregnancy category c. no adequate and well controlled studies have been conducted with a

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

j&j company - hyaluronate sodium (unii: yse9ppt4th) (hyaluronic acid - unii:s270n0trqy) - it has a strong sun block and waterproof function. it contains a large amount of hyaluronic acid to prevent evaporation of moisture from the skin. at the end of skin care, take an appropriate amount and apply evenly over the skin